Маркеры апоптоза и аутоиммунной деструкции бета-клеток при впервые выявленном сахарном диабете 1 типа
Диссертация
Значительный рост заболеваемости сахарным диабетом (СД) обусловил принятие Организацией Объединённых Наций резолюции по СД в 2006 году, основной целью которой явилось углубление научных исследований в области СД. В настоящее время считается, что ведущими звеньями в патогенезе аутоиммунного поражения ß—клеток поджелудочной железы (ПЖЖ) является нарушение регуляции гомеостаза… Читать ещё >
Список литературы
- Барышников А.Ю., Шишкин Ю. В. Иммунологические проблемы апоптоза. М., 2002. — 320 с.
- Дедов И.И. Новые возможности терапии сахарного диабета 2 типа // Сахарный диабет. спецвыпуск 2009. — С. 1−3.
- Дедов И.И., Никонова Т. В., Смирнова О. М. и др. Роль цитокинов в регуляции иммунного ответа и механизмы гибели ß--клеток при различных вариантах течения сахарного диабета типа 1 // Проблемы эндокринологии. — 2005.-Т. 51, № 3.-С. 3−7.
- Кононенко И.В. Функциональное состояние ß--клеток, периферическая чувствительность к инсулину, метаболизм глюкозы у больных с поздним аутоиммунным началом сахарного диабета в дебюте заболевания: дис.. канд. мед. наук. -М., 2003. 140 с.
- Мейл Д., Бростофф Дж., Рот Д.Б., Ройт А. Иммунология: Пер с англ. -М.: Логосфера, 2007. 568 с.
- Никонова Т.В., Прокофьев С. А., Горелышева В. А. и др. Апоптоз в развитии ремиссии сахарного диабета 1 типа // Сахарный диабет. 2006. -№ 4.-С. 47−50.
- ОдинВ.И. Аутоиммунный сахарный диабет. Под ред. A.A. Новика-СПб: ВМедА, 2003. 344 с.
- ПотапневМ.П. Апоптоз клеток иммунной системы и его регуляция цитокинами // Иммунология. 2002. -№ 4. — С. 237−242.
- Смирнова О.М. Клинические, иммуногенетические, гормонально-метаболические аспекты впервые выявленного инсулинзависимого сахарного диабета (клиника, диагностика, лечение, профилактика): дис.. д-ра мед. наук. -М., 1995.-320 с.
- Эйзенбарт Дж.С., Циглер А. Сахарный диабет 1 типа / Молекулярная эндокринология. Фундаментальные исследования и их отражение в клинике: пер. с англ. // под ред. Б. Д. Вайнтрауба. М.: Медицина, 2003. — С. 262−276.
- Anderson M.S., Bluestone J.A. The NOD mouse: a model of immune dysregulation // Annu. Rev. Immunol. 2005. — Vol. 23. — P. 447−485.
- Anjos S., Polychronakos C. Mechanisms of genetic susceptibility to type I diabetes: beyond HLA // Mol. Genet. Metab. 2004. — Vol. 81. — P. 187−195.
- Atkinson M.A., Eisenbarth G.S. Type 1 diabetes: new perspectives on disease pathogenesis and treatment // Lancet. 2001. — Vol. 358. — P. 221−229.
- AugsteinP., Elefanty A.G., Allison J. et al. Apoptosis and (3-cell destruction in pancreatic islets of NOD mice with spontaneous and cyclophosphamide-accelerated diabetes // Diabetologia. 1998.- Vol. 41.-P. 1381−1388.
- Barker J.M., Triolo T.M., Aly T.A. et al. Two single nucleotide polymorphisms identify the highest-risk diabetes HLA genotype: potential for rapid screening // Diabetes. 2008. — Vol. 57. — P. 3152−3155.
- Behme M.T., Dupre J., Harris S.В. et al. Insulin resistance in latent autoimmune diabetes of adulthood // Ann. N.Y. Acad. Sci. 2003. — Vol. 1005. -P. 374−377.
- Bingley P.J., Bonifacio E., Williams A.J. et al. Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers // Diabetes. 1997. — Vol. 46. — P. 1701−1710.
- Bober E., Diindar В., Biiyiikgebiz A. Partial remission phase and metabolic control in type 1 diabetes mellitus in children and adolescents // J. Pediatr. Endocrinol. Metab. 2001. — Vol. 14. — P. 435−441.
- BorgH., GottsaterA., FernlundP., Sundkvist G. A 12-year prospective study of the relationship between islet antibodies and P-cell function at and after the diagnosis in patients with adult-onset diabetes // Diabetes. 2002. — Vol. 51.-P. 1754−1762.
- Bottini N., Musumeci L., Alonso A. et al. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes // Nat Genet. 2004. -Vol. 36.-P. 337−338.
- Brenner C., CadiouH., VieiraH.L. et al. Bcl-2 and Bax regulate the channel activity of the mitochondrial adenine nucleotide translocator // Oncogene. 2000. — Vol. 19. — P. 329−336.
- Brophy S., Yderstraede K., Mauricio D. et al. Time to insulin initiation cannot be used in defining latent autoimmune diabetes in adults // Diabetes Care. -2008. Vol. 31. — P. 439−441.
- Brown R.J., RotherK.I. Effects of beta-cell rest on beta-cell function: a review of clinical and preclinical data // Pediatr. Diabetes. 2008. — Vol. 9. -P. 14−22.
- Buzzetti R., Di Pietro S., Giaccari A. et al. High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes // Diabetes Care. 2007. — Vol. 30. — P. 932−938.
- Cervin C., Lyssenko V., Bakhtadze E. et al. Genetic similarities between latent autoimmune diabetes in adults, type 1 diabetes, and type 2 diabetes // Diabetes. 2008. — Vol. 57. — P. 1433−1437.
- Chiu H.K., Tsai E.C., Juneja R. et al. Equivalent insulin resistance in latent autoimmune diabetes in adults (LADA) and type 2 diabetes patients // Diabetes Res. Clin. Pract. 2007. — Vol. 77. — P. 237−244.
- Cnop M., Welsh N., Jonas J.C. et al. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities // Diabetes. 2005. — Vol. 54 (Suppl 2). — S. 97−107.
- Cohen J.J., Duke R.C., Fadok V.A. et al. Apoptosis: physiologic cell death //J. Clin. Lab. Med. 1994.-Vol. 124.-P. 761−765.
- CoxN.J., Wapelhorst B., Morrison V.A. et al. Seven regions of the genome show evidence of linkage to type 1 diabetes in a consensus analysis of 767 multiplex families // Am. J. Hum. Genet. 2001. — Vol. 69. — P. 820−830.
- Daneman D. Type 1 diabetes // Lancet. 2006. — Vol. 367. — P. 847−858.
- Darville M.I., Liu D., Chen M-C. et al. Molecular regulation of Fas expression in ?-cells // Diabetes, 2001, 50 (Suppl. 1): S83.
- DecochezK., Truyen I., van der Auwera B. et al. Combined positivity for HLA DQ2/DQ8 and IA-2 antibodies defines population at high risk of developing type 1 diabetes // Diabetologia. 2005. — Vol. 48. — P. 687−694.
- De Franco S., Bonissoni S., Cerutti F. et al. Defective function of Fas in patients with type 1 diabetes associated with other autoimmune diseases // Diabetes.-2001.-Vol. 50.-P. 483−488.
- De Franco S., Chiocchetti A., Ferretti M. et al. Defective function of the Fas apoptotic pathway in type 1 diabetes mellitus correlates with age at onset // Int. J. Immunopathol. Pharmacol. 2007. — Vol. 20. — P. 567−576.
- DesaiM., Clark A. Autoimmune diabetes in adults: lessons from the UKPDS // Diabet. Med. 2008. — Vol. 25 (Suppl. 2). — P. 30−34.
- Desai M., Zeggini E., Horton V.A. et al. An association analysis of the HLA gene region in latent autoimmune diabetes in adults // Diabetologia. -2007.-Vol. 50.-P. 68−73.
- Donath M.Y., StorlingJ., Berchtold L.A. et al. Cytokines and ?-cell biology: from concept to clinical translation // Endocr. Rev. 2008. — Vol. 29. -P. 334−350.
- EguchiK. Apoptosis in autoimmune diseases // Internal. Medicine.-2001.-Vol. 40.-P. 275−284.
- Eisenbarth G.S. Banting Lecture 2009: An unfinished journey: molecular pathogenesis to prevention of type 1A diabetes // Diabetes. 2010. — Vol. 59. -P. 759−774.
- EizirikD.L., Mandrup-Poulsen T. A choice of death the signal-transduction of immune-mediated ?-cell apoptosis // Diabetologia.- 2001.-Vol. 44.-P. 2115−2133.
- EspositoK., Ciotola M., Carleo D. et al. Effect of rosiglitazone onendothelial function and inflammatory markers in patients with the metabolic syndrome // Diabetes Care. 2006. — Vol. 29. — P. 1071−1076.
- Filippi C.M., von Herrath M.G. Viral trigger for type 1 diabetes // Diabetes. 2008. — Vol. 57. — P. 2863−2871
- Fourlanos S., Dotta F., Greenbaum C.J. et al. Latent autoimmune diabetes in adults (LADA) should be less latent // Diabetologia. 2005. — Vol. 48. -P. 2206−2212.
- Fridlyand L.E., Philipson L.H. Does the glucose-dependent insulin secretion mechanism itself cause oxidative stress in pancreatic beta-cells? // Diabetes. 2004. -Vol. 53. — P. 1942−1948.
- Gale E.A.M. Latent autoimmune diabetes in adults: a guide for the perplexed // Diabetologia. 2005. — Vol. 48. — P. 2195−2199.
- Gillespie K.M. Type 1 diabetes: pathogenesis and prevention // CMAJ. -2006.-Vol. 175.-P. 165−170.
- Giordano C., De Maria R., Stassi G. et al. Defective expression of the apoptosiss-inducing CD95 (Fas/APO-1) molecule on T- and B-cells in IDDMV/ Diabetologia. 1995. — Vol. 38. — P. 1449−1454.
- Goldberg E., Krause I. Infection and type 1 diabetes mellitus — A two edged sword? // Autoimmun. Rev. 2009. — Vol. 8. — P. 682−686.
- Gottsater A., Landin-Olsson M., Femlund P. et al. Beta-cell function in relation to islet cell antibodies during the first 3 yr after clinical diagnosis of diabetes in type II diabetic patients // Diabetes Care. 1993. — Vol. 16. — P. 902 910.
- Green D.R. Apoptotic pathways: ten minutes to dead // Cell. 2005.-Vol. 121.-P. 671−674.
- Gronski M.A., Weinem M. Death pathways in T cell homeostasis and their role in autoimmune diabetes // Rev. Diabetic Stud. 2006. — Vol. 3 — P. 88−95.
- Groop L.C., Bottazzo G.F., Doniac D. Islet cell antibodies identify latent type 1 diabetes in patients aged 35−75 years at diagnosis // Diabetes. 1986,1. Vol. 35.-P. 237−241.
- Groop L., Tuomi T., Rowley M. Latent autoimmune diabetes in adults
- DA) more than a name // Diabetologia. — 2006. — Vol. 49. — P. 1996−1998.
- Hale A.J., Smith C.A., Sutherland L.C. et al. Apoptosis: molecular regulation of death // Eur. J. Biochem. 1996. — Vol. 236. — P. 1−26.
- Hagopian W.A., Sanjeevi C.B., Kockum I. et al. Glutamate decarboxylase-insulin-, and islet cell-antibodies and HLA typing to detect diabetes in a general population-based study of Swedish children // J. Clin. Invest. 1995. — Vol. 95. -P. 1505−1511.
- Hagopian W.A., Lernmark A., Rewers M.J. et al. TEDDY The Environmental Determinants of Diabetes in the Young: an observational clinical trial // Ann. NY Acad. Sei. — 2006. — Vol. 1079. — P. 320−326.
- Hummel M., Bonifacio E., Schmid S. et al. Brief communication: early appearance of islet autoantibodies predicts childhood type 1 diabetes in offspring of diabetic parents // Ann. Intern. Med. 2004. — Vol. 140. — P. 882−886.
- Ilonen J., Vaarala O., Akerblom H.K., Knip M. Environmental factors and primary prevention in type 1 diabetes // Pediatr. Endocrinol. Diabetes Metab. -2009.-Vol. 15.-P. 227−232.
- Jahromi M.M., Eisenbarth G.S. Cellular and molecular pathogenesis of type 1A diabetes // Cell Mol. Life Sei. 2007. — Vol. 64. — P. 865−872.
- JunH.S., Yoon J.W. A new look at viruses in type 1 diabetes // Diabetes Metab. Res. Rev. -2003. Vol. 19. -P. 8−31.
- Kabelitz D., Pohl T., Pechhold K. Activation-induced cell death (apoptosis) of mature peripheral T lymphocytes // Immunol. Today. 1993. — Vol. 14.-P. 338−339.
- Kharroubi I., Ladriere L., Cardozo A.K. et al. Free fatty acids and cytokines induce pancreatic P-cell apoptosis by different mechanisms: role of nuclear factor-kappa B and endoplasmic reticulum stress // Endocrinology.2004.-Vol. 145.-P. 5087−5096.
- Kim M.S., Polychronakos C. Immunogenetics of type 1 diabetes. // Horm. Res. 2005, 64: 180−188.
- Knip M. Natural course of preclinical type 1 diabetes // Horm. Res. -2001. Vol. 57 (Suppl 1). — P. 6−11.
- Knip M. Can we predict type 1 diabetes in general population? // Diabetes Care. 2002. — Vol. 25. — P. 623−625.
- Knip M. Autoimmune mechanisms in type 1 diabetes // Autoimmunity Rev. 2008. — Vol. 7. — P. 550−557.
- KnipM., KorhonenS., KulmalaP. et al. Prediction of type 1 diabetes in the general population // Diabetes Care. -2010. Vol. 33. — P. 1206−1212.
- Knip M., Kukko M., KulmalaP. et al. Humoral beta-cell autoimmunity in relation to HLA-defined disease susceptibility in preclinical and clinical type 1 diabetes // Am. J. Med. Genet. 2001. — Vol. 115. — P. 48−54.
- Kobayashi T., Maruyama T., Shimada A. et al. Insulin intervention to preserve p-cells in slowly progressive insulin-dependent (type 1) diabetes mellitus // Ann. NY Acad. Sci. 2002. — Vol. 958. — P. 117−130.
- KukrejaA., Cost G., Marker J. et al. Multiple immuno-regulatory defectsin type 1 diabetes//J. Clin. Invest. 2002. — Vol. 109.-P. 131−140.
- Kulmala P. et al. Prediction of insulin-dependent diabetes mellitus in siblings of children with diabetes: a population-based study // J. Clin. Invest. -1998.-Vol. 101.-P. 327−336.
- Kupila A., Keskinen P., Simell T. et al. Genetic risk determines the emergence of diabetes-associated autoantibodies in young children // Diabetes. -2002.-Vol. 51.-P. 646−651.
- Lee S.C., Pervaiz S. Apoptosis in the pathophysiology of diabetes mellitus // Int. J. Biochem. Cell Biology. 2007. — Vol. 39. — P. 497−504.
- LechnerH., Amort M., StegerM.M. et al. Regulation of CD95 (APO-1) expression and the induction of apoptosis in human T cells: changes in old age // Int. Arch. Allergy Immunol. 1996. — Vol. 110. — P. 238−243.
- Leslie D., Lipsky P., Notkins A.L. Autoantibodies as predictors of disease //J. Clin. Invest.-2001.-Vol. 108.-P. 1417−1422.
- Leslie R.D., Atkinson M.A., Notkins A.L. Autoantigens IA-2 and GAD in type I (insulin-dependent) diabetes // Diabetologia. 1999. — Vol. 42. — P. 3−14.
- Lohmann T., Seissler J., Verlohren H.J. et al. Distinct genetic and immunological features in patients with insulin-dependent diabetes below and above age 40 at onset // Diabetes Care. 1997. — Vol. 20. — P. 524−529.
- Loweth A.C., Williams G.T., James R.F. et al. Human islets of Langerhans express Fas ligand and undergo apoptosis in response to interleukin-l{3 and Fas ligation // Diabetes. 1998. — Vol. 47. — P. 727−732.
- Maclaren N.K., LanM.S., SchatzD. et al. Multiple autoantibodies as predictors of type 1 diabetes in a general population // Diabetologia. 2003.-Vol. 46.-P. 873−874.
- Maedler K., Fontana A., Ris F. et al. FLIP switches Fas-mediated glucose signaling in human pancreatic beta cells from apoptosis to cell replication // Proc. Natl. Acad. Sci. USA. -2002. Vol. 99. — P. 8236−8241.
- Maedler K., Spinas G.A., LehmannR. Glucose induced (3-cell apoptosisvia upregulation of the Fas receptor in human islets // Diabetes. 2001.-Vol. 50.-P. 1683−1690.
- Mandrup-Poulsen T. The role of interleukin-1 in the pathogenesis of IDDM//Diabetologia. 1996. -Vol. 39.-P. 1005−1029.
- Mandrup-Poulsen T. P-Cell apoptosis: stimuli and signaling // Diabetes. -2001.-Vol. 50 (Suppl 1). S 58−63.
- Mathis D., Vence L., Benoist C. P-Cell death during progression to diabetes // Nature. 2001. — Vol. 414. — P. 792−798.
- Miao D., Yu L., Eisenbarth G.S. Role of autoantibodies in type 1 diabetes //Front Biosci.-2007.-Vol. 12.-P. 1889−1898.
- Moriwaki M., Itoh N., Miyagawa J. et al. Fas and Fas ligand expression in inflamed islets in pancreas sections of patients with recent-onset type I diabetes mellitus //Diabetologia. 1999. — Vol. 42. — P. 1332−1340.
- MorranM.P., Omenn G.S., Pietropaolo M. Immunology and genetics of type 1 diabetes // Mt. Sinai J. Med. 2008. — Vol. 75. — P. 314−327.
- Moulian N., Berrih-Aknin S. Fas/APO-l/CD95 in health and autoimmune disease: thymic and peripheral aspects // Semin. Immunol. 1998.- Vol. 10.-P. 449−456.
- Nagata S. Apoptosis by death factor // Cell. 1997. — Vol. 88. — P. 355 365.
- NaikR.G., Brooks-Worrell B.M., Palmer J.P. Latent autoimmune diabetes in adults // J. Clin. Endocrinol. Metab. 2009. — Vol. 94. — P. 4635−4644.
- NotkinsA.L., LernmarkA. Autoimmune type 1 diabetes: resolved and unresolved issues//J. Clin. Invest. 2001. — Vol. 108. — P. 1247−1252.
- Palmer J.P. Beta cell rest and recovery does it bring patients with latentautoimmune diabetes in adults to euglycemia? // Ann. NY Acad. Sci. 2002. -Vol. 958.-P. 89−98.
- Palmer J.P., Hampe C.S., Chiu H. et al. Is latent autoimmune diabetes in adults distinct from type 1 diabetes or just type 1 diabetes at an older age? // Diabetes. 2005. — Vol. 54. — S62-S67.
- Palmer J.P., Hirsch I.B. What’s in a name: latent autoimmune diabetes of adults, type 1.5, adult-onset, and type 1 diabetes // Diabetes Care. 2003.-Vol. 26.-P. 536−538.
- Pearl-Yafe M., Kaminitz A., Yolcu E.S. et al. Pancreatic islets under attack: cellular and molecular effectors // Curr. Pharm. Des. 2007. — Vol. 13. -P. 749−760.
- PetroneA., Galgani A., Spoletini M. et al. Residual insulin secretion at diagnosis of type 1 diabetes is independently associated with both, age of onset and HLA genotype // Diabetes Metab. Res. Rev. 2005. — Vol. 21. — P. 271−275.
- Pinkse G.G., Tysma O.H., Bergen C.A. et al. Autoreactive CD 8 T-cells associated with p-cell destruction in type 1 diabetes // Proc. Natl. Acad. Sci. USA.-Vol. 102.-P. 18 425−18 430.
- PirotP., Cardozo A.K., EizirikD.L. Mediators and mechanisms of pancreatic P-cell death in type 1 diabetes // Arq. Bras. Endocrinol. Metab. -2008.-Vol. 52.-P. 156−165.
- Pozzilli P., Di Mario U. Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adult): definition, characterization, and potential prevention // Diabetes Care. 2001. — Vol. 24. — P. 1460−1467.
- Pozzilli P., Manfrini S., Buzzetti R. et al. Glucose evaluation trial for remission (GETREM) in type 1 diabetes: a European multicentre study // Diabetes Res. Clin. Pract. 2005. — Vol. 68. — P. 258−264.
- Rathmell J.C., Thompson C.B. The central effectors of cell death in immune system // Annu. Rev. Immunol. 1999. — Vol. 17. — P. 781−828.
- Redondo M.J., Eisenbarth G.S. Genetic control of autoimmunity in type I diabetes and associated disorders // Diabetologia. 2002. — Vol. 45. — P. 605−622.
- Redondo M.J., FainP.R., Eisenbarth G.S. Genetics of type 1A diabetes // Recent Prog. Horm. Res. 2001. — Vol. 56. — P. 69−89.
- Richer M.J., HorwitzM.S. Viral infections in the pathogenesis of autoimmune diseases: focus on type 1 diabetes // Front. Biosci.- 2008. Vol. 13. -P. 4241−4257.
- Roep B.O. The role of T-cells in the pathogenesis of type 1 diabetes: from cause to cure // Diabetologia. 2003. — Vol. 46. — P. 305−21.
- RosarioP.W., Reis J.S., Amim R. et al. Comparison of clinical and laboratory characteristocs between adult-onset type 1 diabetes and latent autoimmune diabetes in adult // Diabetes Care. 2005. — Vol. 28. — P. 1803−1804.
- RutterG.A., WongF.S. The pancreatic p-cell: birth, life and death // Biochem. Soc. Trans. 2008. — Vol. 36. — P. 267−271.
- Scaffidi C., Schmitzl., ZhaJ. et al. Differential modulation of apoptosis sensitivity in CD95 type I and type II // J. Biol. Chem. 1999.- Vol. 274.-P. 22 532−22 538.
- SchranzD.B., BerkisL., Landin-Olsson M. et al. Newly diagnosed latent autoimmune diabetes in adults (LADA) is associated with low level glutamate decarboxylase (GAD65) and IA-2 autoantibodies // Horm. Metab. Res. 2000. Vol. 32.-P. 133−138.
- SchatzD.A., MaclarenN.K. The natural history of pre-type 1 diabetes // Current Science. 1995. — Vol. 2. — P. 31−37.
- Schmidt K.D., Valeri C., Leslie R.D. Autoantibodies in type 1 diabetes // Clin. Chim. Acta. 2005. — Vol. 354. — P. 35−40.
- Service F.J., RizzaR.A., Zimmerman B.R. et al. The classification of diabetes by clinical and C-peptide criteria: a prospective population-based study // Diabetes Care. 1997. — Vol. 20. — P. 198−201.
- Shaw J.E., Sicree R.A., Zimmet P.Z. Global estimates of the prevalence of diabetes for 2010 and 2030 // Diabetes Res. Clin. Pract. 2010. — Vol. 87. — P. 414.
- ShoenfeldY., Blank M., Abu-Shakra M. et al. The mosaic of autoimmunity: prediction, autoantibodies, and therapy in autoimmune diseases // Isr. Med. Assoc. J. 2008. — Vol. 10. — P. 13−19.
- Taplin C.E., Barker J.M. Autoantibodies in type 1 diabetes // Autoimmunity.-2008.-Vol. 41.-P. 11−18.
- Thomas H.E., DarwicheR., CorbettJ.A., Kay T.W. Interleukin-1 plus gamma-interferon-induced pancreatic beta-cell dysfunction is mediated by beta-cell nitric oxide production // Diabetes. 2002. — Vol. 51. — P. 311 -316.
- Thomson G., Valdes A.M., Noble J.A. et al. Relative predispositional effects of HLA class II DRB1-DQB1 haplotypes and genotypes on type 1 diabetes: a meta-analysis // Tissue Antigens. 2007. — Vol. 70. — P. 110−127.
- ToddJ.A., Walker N.M., Cooper J.D. et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes // Nat. Genet. 2007. — Vol. 447. — P. 661−678.
- Tuomi T., CarlssonA., Li H. et al. Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies // Diabetes. 1999. — Vol 48.1. P. 150−157.
- Tuomi T., Groop L.C., ZimmetP.Z. et al. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease // Diabetes. 1993. — Vol. 42. — P. 359−362.
- Verge C.F., Gianani R., Kawasaki E. et al. Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies // Diabetes. 1996. — Vol. 45. — P. 926−933.
- Walczak H., Krammer P.H. The CD95 (APO-l/Fas) and the TRAIL (APO-2L) apoptosis system // Exp. Cell Res. 2000. — Vol. 256. — P. 58−66.
- WenzlauJ.M., Juhl K., YuL. et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes // Proc. Natl. Acad. Sci. USA.-2007.-Vol. 104.-P. 17 040−17 045.
- Wenzlau J.M., Moua O., Sarkar S.A. et al. SLC30A8 is a major target of humoral autoimmunity in type 1 diabetes and a predictive marker in prediabetes // Ann. NY Acad. Sci. 2008. — Vol. 1150. — P. 256−259.
- Wong F.S., Wen L. The study of HLA class II and autoimmune diabetes // Curr. Mol. Med. 2003. — Vol. 3. — P. 1−15.
- YoonJ.W., JunH.S. Cellular and molecular pathogenic mechanisms of insulin-dependent diabetes mellitus // Ann. NY Acad. Sci. 2001. — Vol. 928. -P. 200−211.
- Yoon J.W., Jun H.S. Autoimmune destruction of pancreatic p-cells. // Am.
- J. Ther.-2005.- Vol. 12.-P. 580−591.
- Yoon J.W., JunH.S., Santamaria P. Cellular and molecular mechanisms for the initiation and progression of -beta-cell destruction resulting from the collaboration between macrophages and T cells // Autoimmunity.- 1998.-Vol. 127.-P. 109−112.
- Zimmet P.Z. The pathogenesis and prevention of diabetes in adults // Diabetes Care. 1995. -Vol. 18.-P. 1050−1064.
- Zimmet P.Z., Tuomi T., Mackay I.R. et al. Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency // Diabet. Med.- 1994.-Vol. 11.-P. 299−303.
- Zimmet P.Z., Turner R., McCarty D. et al. Type 2 or slow type 1 diabetes // Diabetes Care. 1999. — Vol. 22 (Suppl 2). — P. 59−64.
- ZinmanB., Kahn S.E., Haffner S.M. et al. Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe // Diabetes. 2004. — Vol. 53. — P. 3193−3200.
- Zoledziewska M., Perra C., Orru V. et al. Further evidence of a primary, causal association of the PTPN22 620W variant with type 1 diabetes // Diabetes. -2008. Vol. 57. — P. 229−234.